Evrin, 50 mg/ml 5 ml 5 pcs

.

Indications

– Acute cerebrovascular accidents (as part of complex therapy);

– traumatic brain injury, consequences of traumatic brain injury;

– dyscirculatory encephalopathy;

– syndrome of vegetative (neurocirculatory) dystonia;

– mild cognitive disorders of atherosclerotic origin;

– anxiety disorders in neurotic and neurosis-like conditions;

– acute myocardial infarction (from the first day) as part of complex therapy;

– primary open-angle glaucoma of various stages, as part of complex therapy;

– relief of withdrawal syndrome in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders;

– acute intoxication with antipsychotic drugs;

– acute purulent-inflammatory processes of the abdominal cavity (acute necrotizing pancreatitis, peritonitis) as part of complex therapy.

Pharmacological effect

Pharmacotherapeutic group: Antioxidant

ATC: N.07.X.X Other drugs for the treatment of diseases of the nervous system
Pharmacodynamics:

Ethylmethylhydroxypyridine succinate belongs to the class of 3-hydroxypyridines, is an inhibitor of free radical processes, and a membrane protector. It also has an antihypoxic effect and increases the body’s resistance to stress.

The mechanism of action of ethylmethylhydroxypyridine succinate is due to its antioxidant and membrane protective effect. The drug inhibits lipid peroxidation, increases the activity of superoxide oxidase, increases the lipid-protein ratio, and improves the structure and function of the cell membrane.

Ethylmethylhydroxypyridine succinate models the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, gamma-aminobutyric, acetylcholine), which enhances their ability to bind to ligands, contributes to the preservation of the structural and functional organization of biomembranes, neurotransmitter transport and improvement synaptic transmission. Ethylmethylhydroxypyridine succinate increases dopamine levels in the brain. Causes an increase in compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under hypoxic conditions with an increase in the content of adenosine triphosphate (ATP) and creatine phosphate, activation of the energy-synthesizing functions of mitochondria.

Increases the body’s resistance to the effects of various damaging factors in pathological conditions (hypoxia and ischemia, cerebrovascular accidents, intoxication with ethanol and antipsychotic drugs).

In conditions of a critical decrease in coronary blood flow, it helps to preserve the structural and functional organization of cardiomyocyte membranes, stimulates the activity of membrane enzymes – phosphodiesterase, adenylate cyclase, acetylcholinesterase. Supports the activation of acetylcholinesterase that develops during acute ischemia. Supports the activation of aerobic glycolysis that develops during acute ischemia and promotes the restoration of mitochondrial redox processes under hypoxic conditions, increases the synthesis of ATP and creatine phosphate.

Ensures the integrity of the morphological structures and physiological functions of the ischemic myocardium. Improves the clinical course of myocardial infarction, increases the effectiveness of therapy, reduces the incidence of arrhythmias and intracardiac conduction disorders.

Normalizes metabolic processes in ischemic myocardium, increases the antianginal activity of nitrates, improves the rheological properties of blood, reduces the consequences of reperfusion syndrome in acute coronary insufficiency.

Promotes the preservation of retinal ganglion cells and optic nerve fibers during progressive neuropathy, the causes of which are chronic ischemia and hypoxia. Improves the functional activity of the retina and optic nerve, increasing visual acuity.

Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.

Improves metabolism and blood supply to the brain, microcirculation and rheological properties of blood, reduces platelet aggregation. Stabilizes the membranes of blood cells (erythrocytes and platelets), reducing the likelihood of hemolysis. It has a lipid-lowering effect by reducing the content of total cholesterol and low-density lipoproteins.

Pharmacokinetics:

Suction

With a single and course dose, the maximum concentration (Cmax) in the blood plasma is achieved after 0.58 hours. When administered at a dose of 400-500 mg, Cmax in the blood plasma is 3.5-4 μg/ml.

Distribution

Quickly distributed in organs and tissues. The average retention time of ethylmethylhydroxypyridine succinate in the body is 0.7-1.3 hours.

Metabolism

Metabolized in the liver by glucuronidation. 5 metabolites have been identified: 3-hydroxypyridine phosphate – formed in the liver and, with the participation of alkaline phosphatase, breaks down into phosphoric acid and 3-hydroxypyridine; 2nd metabolite – pharmacologically active, formed in large quantities and found in urine 1-2 days after administration; 3rd – excreted in large quantities in the urine; 4th and 5th – glucuron conjugates.

Removal

It is eliminated from blood plasma quickly and is practically undetectable after 4 hours in it. It is rapidly excreted in the urine, mainly in the form of metabolites (50% in 12 hours), and in small quantities unchanged (0.3% in 12 hours). The urinary excretion rates of unchanged ethylmethylhydroxypyridine succinate and metabolites have individual variability.

Special instructions

The drug is not prescribed to children under 18 years of age due to insufficient knowledge of the drug’s effect.

Impact on the ability to drive vehicles. Wed and fur.:

During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Active ingredient

Ethylmethylhydroxypyridine succinate

Composition

1 ml of the drug contains:

Active ingredient:

Ethylmethylhydroxypyridine succinate – 50.0 mg

Excipients:

Sodium disulfite – 0.47 mg,

Water for injection up to 1.0 ml

Pregnancy

Experimental studies did not reveal teratogenic, mutagenic or embryotoxic effects. Adequate and strictly controlled clinical studies have not been conducted during pregnancy and lactation. The drug is contraindicated during pregnancy and breastfeeding due to insufficient data on the effectiveness and safety of the drug during these periods.

Contraindications

– Hypersensitivity to the drug;

– acute liver and/or kidney failure;

– children’s age;

– pregnancy;

– breastfeeding period – due to the lack of data on effectiveness and safety.

With caution:

History of allergic diseases.

Side Effects

From the digestive system: nausea, dry oral mucosa or metallic taste in the mouth, flatulence, diarrhea.

From the nervous system: drowsiness, difficulty falling asleep.

From the respiratory system: sore throat, chest discomfort, feeling of lack of air (usually associated with an excessively high rate of administration and is short-term in nature).

From the cardiovascular system: short-term increase in blood pressure.

Other: allergic reactions, feeling of “spreading warmth” throughout the body, unpleasant odor.

Interaction

Enhances the effect of benzodiazepine anxiolytics, antiepileptic (carbamazepine), antiparkinsonian (levodopa) drugs.

Reduces the toxic effect of ethanol.

Overdose

Due to low toxicity, overdose is unlikely. In case of accidental overdose, sleep disturbance (insomnia), in some cases drowsiness and sedation, may occur. When administered intravenously, an increase in blood pressure is possible.

Treatment

As a rule, it is not required – the symptoms disappear on their own within 24 hours. In especially severe cases of insomnia, it is recommended to use one of the sleeping pills and anxiolytics for oral administration (nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg). If blood pressure is excessively high, use antihypertensive drugs under blood pressure control.

Storage conditions

In consumer packaging, at a temperature not exceeding 25 °C.

Keep out of the reach of children.

Shelf life

3 years.

Do not use after the expiration date.

Manufacturer

Grotex LLC, Russia